Interoperability APIs, the Ontology Test Clinical Trials Keep Failing
The week’s signal
The interoperability conversation around clinical trials keeps landing on the same uncomfortable truth: APIs only help when the meaning underneath them is stable. In practice, the work is not just moving data between CDISC and FHIR, but resolving entities, automating metadata, and turning clinical data into reusable products that can survive both R&D workflows and care delivery workflows.
That is also why the usual API pitch frustrates senior engineering and R&D teams. It talks about exchange, but it skips the semantic gap between trial design and the electronic health record, where protocol intent, site practice, and source system structure do not line up cleanly.
Why adoption is hard
CDISC to FHIR mapping is not a field matching exercise. It requires ontology governance: agreeing on what a variable means, which resource represents it, how provenance is preserved, and when a transformation is validated enough to trust in a regulated workflow.
That governance burden is why teams stall. Once you move beyond a demo site, the same clinical concept can be modeled differently across hospitals, vendors, and study teams, so metadata automation starts failing exactly where people hoped it would remove friction. The promise is clean interoperability, but the reality is a pile of edge cases, local conventions, and manual exceptions that keep coming back.
Entity resolution is the operational core of that problem. If a trial variable cannot be resolved to a stable clinical entity, the API cannot reliably decide whether it maps to an Observation, a Condition, a MedicationStatement, or something else entirely.
What failure looks like
Failure shows up as inconsistency disguised as integration.
An API can look healthy and still return different endpoints, different mappings, or different payload shapes depending on the site, because the underlying CDISC variables were never resolved to FHIR resources in a governed way. At that point, the interface is not really delivering interoperability. It is exposing unresolved ambiguity at higher speed.
This is where engineering teams feel the pain most directly. Every exception becomes manual reconciliation, every manual fix becomes another mapping rule, and every new rule widens the gap between the intended model and the one actually running in production. That is how metadata automation fails in the real world: not with a dramatic outage, but with quiet divergence that makes the data less trustworthy over time.
The systems implication
The deeper shift is that interoperability APIs are becoming the only credible way to make clinical data reusable across R&D and clinic. FHIR can act as the access layer, and in some settings even as an eSource or submission format, but the value comes from preserving origin, attribution, timing, and change controlled mappings that can be audited and reused.
That matters because pharma does not need another thin integration layer that merely passes bytes around. It needs a data product that can survive regulated review, support downstream clinical decisions, and still remain intelligible when a study moves from protocol design into site execution and eventually into broader real world use.
The hard part is that this is as much an organizational problem as a technical one. If the ontology is not governed, the API inherits the confusion. If the data model diverges across sites, the metadata layer cannot paper over it. And if the system cannot preserve semantic alignment, then “interoperable” becomes a label rather than a capability.
The question underneath the question
If your API cannot map a CDISC variable to a FHIR resource, is it an API problem or an ontology failure?
If you are seeing this in your own stack, the more interesting comparison is usually not vendor versus vendor. It is whether your team is treating interoperability as transport or as shared meaning.